Fecal Calprotectin Levels in Mycophenolate Mofetil Induced Diarrhea and Treatment With Octreotide

Last updated: November 28, 2016
Sponsor: University Health Network, Toronto
Overall Status: Trial Status Unknown

Phase

N/A

Condition

Colic

Organ Transplant

Lactose Intolerance

Treatment

N/A

Clinical Study ID

NCT02977897
16-5998
  • Ages 18-75
  • All Genders

Study Summary

Prospective, observational pilot study of ten post-transplant patients presenting with diarrhea while taking Mycophenolate Mofetil (MMF). These patients will undergo a standard workup to confirm MMF induced diarrhea. A stool fecal calprotectin will be measured to determine if it may be helpful in confirming the diagnosis of MMF associated diarrhea. Once the diagnosis is confirmed, the patients will then be treated with a short course of subcutaneous Octreotide which has been shown to cure this type of diarrhea.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male and female patients between the ages of 18 and 75 years old who are solid organtransplant recipients followed at Toronto General Hospital on MMF referred togastroenterology for diarrhea.

Exclusion

Exclusion Criteria:

  1. Subjects with a known history of IBD or GVHD of the bowel.

  2. Any subject receiving Octreotide for another indication.

  3. Any patient unable to undergo endoscopy.

  4. Any patient with a contraindication to Octreotide therapy.

Study Design

Total Participants: 10
Study Start date:
January 01, 2017
Estimated Completion Date:

Connect with a study center

  • Toronto General Hospital, University Health Network

    Toronto, Ontario M5G 2N2
    Canada

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.